Stockreport

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent ß-Thalassemia at 60th Annual Meeting of the American Society of Hematology

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF First presentation of data from patients with a ß0/ß0 genotype and a pediatric patient treated with LentiGlobin in Phase 3 Northstar-3 study both have st [Read more]